Roche, Axiogenesis Sign Co-Development and Marketing Agreement for Cell Lines | GenomeWeb

Roche, Axiogenesis Sign Co-Development and Marketing Agreement for Cell Lines

Dec 09, 2008

NEW YORK (GenomeWeb News) – Roche announced today that it will team up with Cologne, Germany-based Axiogenesis to develop and distribute Axiogenesis’ Cor.At cell line — specialized heart muscle cells that were derived from embryonic stem cells — in conjunction with the Roche xCELLigence platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.